| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Myriocin targets serine palmitoyltransferase (SPT), a key enzyme in the de novo synthesis of sphingolipids. SPT catalyzes the first and rate-limiting step in sphingolipid biosynthesis, the condensation of L-serine and palmitoyl-CoA to form 3-ketosphinganine. Myriocin acts as a potent, irreversible inhibitor of SPT, blocking the production of sphingolipids and modulating sphingolipid-mediated signaling pathways.
|
|---|---|
| ln Vitro |
Myriocin (Thermozymocidin; 0-10000 nM; 96 h; Huh7/Rep-Feo cells) suppresses the replication of the subgenomic hepatitis C virus (HCV) genotype 1b replicon [2]. Myriocin (100 nM; 72 hours) decreases sphingomyelin levels in Huh7 cells [2].
In vitro, Myriocin is a potent inhibitor of serine palmitoyltransferase, blocking the first step in sphingosine biosynthesis. It has been shown to induce apoptosis in various cell types and exhibits antibacterial, antifungal, and immunosuppressive activities. The compound is commonly used in research to explore the therapeutic potential of modulating sphingolipid pathways for the treatment of various diseases. |
| ln Vivo |
Myriocin (Thermozymocidin; 0–1 mg/kg; intraperitoneally; daily for 5 days; male Balb/c mice) induces the expression of c-myc in the liver and inhibits SPT, thereby blocking de novo sphingolipid synthesis in vivo [1].
In vivo, Myriocin has been used to study the role of sphingolipids in various physiological and pathological processes. By inhibiting SPT, the compound reduces sphingolipid levels in tissues, which can affect inflammation, immune responses, and tumor growth. Myriocin has shown efficacy in preclinical models of autoimmune diseases, metabolic disorders, and cancer. |
| Enzyme Assay |
In vitro enzyme assays for SPT inhibition involve incubating microsomal preparations containing SPT enzyme with L-[³H]-serine and palmitoyl-CoA in the presence of varying concentrations of Myriocin. The production of [³H]-3-ketosphinganine is measured by scintillation counting after extraction. IC50 values are calculated from dose-response curves to determine the compound's potency.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: Huh7/Rep-Feo Cell Tested Concentrations: 0, 300 and 1000 nM Incubation Duration: 96 hrs (hours) Experimental Results: HCV NS5A levels diminished in a concentration-dependent manner. Cellular assays are performed using various cell lines, including immune cells, cancer cells, and metabolic cell types. Cells are treated with Myriocin at various concentrations, and sphingolipid levels (sphingosine, sphinganine, ceramide) are measured by LC-MS/MS. Cell viability, apoptosis, and inflammatory marker expression are assessed to evaluate the biological effects of SPT inhibition. |
| Animal Protocol |
Animal/Disease Models: Male Balb/c mouse (22 g, 7-8 weeks old) [1]
Doses: 0, 0.1, 0.3, and 1.0 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 5 days Experimental Results: Plasma Alanine aminotransferase and aspartate aminotransferase levels were not Dramatically altered. Free dihydrosphingosine was diminished in the liver and kidneys in a dose-dependent manner. Liver SPT activity diminished, with a correlation coefficient of -0.76. Increases hepatic c-myc expression in a dose-dependent manner. In vivo studies are conducted in mouse models of autoimmune diseases (e.g., experimental autoimmune encephalomyelitis), metabolic disorders (e.g., high-fat diet-induced obesity), or cancer. Myriocin is administered intraperitoneally or orally at various doses. Sphingolipid levels in tissues are measured by LC-MS/MS. Disease progression, inflammatory markers, and tumor growth are monitored to evaluate efficacy. |
| ADME/Pharmacokinetics |
Myriocin (molecular weight 401.54, formula C₂₁H₃₉NO₆) is a fungal metabolite. It is a potent and irreversible inhibitor of SPT. The compound is typically stored at -20°C and is soluble in DMSO and ethanol. Its physicochemical properties support its use in both in vitro and in vivo studies.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies have evaluated Myriocin in animal models. As an SPT inhibitor, its toxicity profile is related to disruption of sphingolipid biosynthesis, which can affect cell membrane integrity and signaling. The compound has demonstrated dose-dependent toxicity, with careful dose titration required for in vivo studies.
|
| References |
|
| Additional Infomation |
Myriocin are amino acid antibiotics derived from certain thermophilic fungi that effectively inhibit serine palmitoyltransferase (the first step in sphingosine biosynthesis). Myriocin also possess immunosuppressive activity. They exhibit multiple functions, including antibacterial, antifungal, immunosuppressive, EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor, apoptosis inducer, antitumor, and antifungal metabolite activity. They are sphingosine compounds, α-amino fatty acids, non-protein α-amino acids, and hydroxy monocarboxylic acids. Myriocin have been reported to exist in Melanocarpus albomyces, Streptomyces, and other organisms with relevant data.
Myriocin (ISP-1, Thermozymocidin) is a potent, irreversible inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in sphingolipid biosynthesis. It is a fungal metabolite with antibacterial, antifungal, immunosuppressive, and antitumor activities. The compound is widely used as a research tool to study sphingolipid biology and the therapeutic potential of modulating sphingolipid pathways for the treatment of autoimmune diseases, metabolic disorders, and cancer. Myriocin has not received regulatory approval for clinical use. |
| Molecular Formula |
C21H39NO6
|
|---|---|
| Molecular Weight |
401.5375
|
| Exact Mass |
401.277
|
| CAS # |
35891-70-4
|
| PubChem CID |
6438394
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
636.7±55.0 °C at 760 mmHg
|
| Flash Point |
338.8±31.5 °C
|
| Vapour Pressure |
0.0±4.3 mmHg at 25°C
|
| Index of Refraction |
1.522
|
| LogP |
4.21
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
28
|
| Complexity |
468
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCCCCCC(=O)CCCCCC/C=C/C[C@H]([C@@H]([C@@](CO)(C(=O)O)N)O)O
|
| InChi Key |
ZZIKIHCNFWXKDY-ANSFIGKPSA-N
|
| InChi Code |
InChI=1S/C21H39NO6/c1-2-3-4-10-13-17(24)14-11-8-6-5-7-9-12-15-18(25)19(26)21(22,16-23)20(27)28/h9,12,18-19,23,25-26H,2-8,10-11,13-16,22H2,1H3,(H,27,28)/b12-9+/t18-,19-,21+/m0/s1
|
| Chemical Name |
(2R,3R,4S,E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
|
| Synonyms |
Thermozymocidin; ISP-I; ISP I; ISP1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.86 mg/mL (~7.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.29 mg/mL (0.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 0.29 mg/mL (0.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.9 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 5 mg/mL (12.45 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4904 mL | 12.4521 mL | 24.9041 mL | |
| 5 mM | 0.4981 mL | 2.4904 mL | 4.9808 mL | |
| 10 mM | 0.2490 mL | 1.2452 mL | 2.4904 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA